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Sunlmary 
The 2C T  cell is a CD8 +, alloreactive T  cell, which recognizes ceils bearing L  d and K bm3 class I 
major histocompatability complex molecules. Here, we characterize an allopeptide, designated 
dEV-8, that is a ligand in the K b"~3 molecule for the 2C TC1K but is not a ligand in the L  d mol- 
ecule. By biochemical and immunological properties, dEV-8 is distinct from P2Ca, the L  d al- 
lopeptide that is also recognized by the 2C TC1K.  Using the deduced amino acid sequence of 
dEV-8,  we  isolate a  candidate  endogenous  source  of the  peptide.  The  endogenous  protein, 
ML1KQ, contains a peptide sequence identical to dEV-8.  This degenerate recognition of two 
distinct peptide/MHC complexes by a single TC1K has important implications for understand- 
ing allorecognition. 
M 
ajor histocompatibility complex (MHC) class I mol- 
ecules bind 8-10 amino acid peptides from intracel- 
lular sources and display them at the cell surface for recog- 
nition by T  cell receptors (TCR).  If the peptide is from a 
viral or tumor specific protein,  the  peptide/MHC  class  I 
complex often elicits a CD8 +, cytotoxic T lymphocyte (CTL) 
response.  Peptides  derived  from  normal  self proteins  are 
usually not antigenic and are thought to be involved in se- 
lective events during thymic development (1),  but normal 
self peptides can play a role in recognition by TCIKs when 
presented by non-self MHC antigen presenting molecules 
during an alloresponse (2,  3).  Currently,  the exact role of 
selfpeptides in an alloresponse is still being defined (4). 
One distinguishing feature of allorecognition is the high 
precursor  frequency of responding  T  cells  (5).  This  phe- 
nomenon could be attributed to the innate ability of TC1Ks 
to  associate  with  multiple  MHC  molecule/peptide  com- 
plexes (6). Thymic development is the first situation where 
TC1Ks  contact  MHC/peptide  complexes  (7),  T  cells  are 
presumably selected on selfMHC/peptide structures, and if 
sufficient signals  are generated, the T  cells mature and exit 
the thymus. Once in the periphery, T  cells  are capable of 
being  stimulated  by MHC  molecules  presenting  non-self 
peptides such as viral peptides. The fundamental,  cross re- 
active nature of the TC1K allows a single receptor to be se- 
lected on one set ofpeptide ligands in the thymus and stim- 
ulated by a second set ofligands in the periphery. This leads 
to  the  hypothesis  that  the  ability  of the  TC1K to  engage 
MHC molecules presenting different peptides results in the 
high precursor frequency of alloreactive T  ceils. 
Although MHC molecules are highly polymorphic, they 
all  have  the  shared  function  of  presenting  peptides  to 
TC1Ks.  While  class I  molecules differ from each other by 
up to 20% of their amino acids in the antigen binding do- 
mains  (8),  the amino acid residues believed to contact the 
TC1K are highly conserved. It is the amino acids within the 
peptide  binding  groove where  the  major  differences  be- 
tween  MHC  molecules  exist.  These  differences  can  alter 
the  type  of peptide  bound  and  the  conformation  of the 
MHC molecules. The inordinate number of alloreactive T 
ceils may therefore be explained by the inherent ability of 
TC1Ks to combine with MHC molecules and the fact that 
different MHC  molecules bind  a  variety of distinct  pep- 
tides.  Several labs have shown that these  types of interac- 
tions do play a role in allorecognition. Alloreactive TCIKs 
have the  structural  capability to recognize  conformational 
differences  (9);  differences  on the  ot helices  (10,  11);  and 
even multiple peptides (12).  An allo-MHC molecule is in 
effect a  complex  set  of many different  antigenic  entities, 
each of which can stimulate a small set ofT cells. The sum 
of the T  cell populations is responsible for the vigorous al- 
loresponse. 
While it is apparent that the elasticity of the T  cell recep- 
tor is a central feature of this molecule, the structural basis 
for these interactions is not understood.  To date there has 
been no defined set of distinct ligands that are recognized 
by a single alloreactive TC1K. In this report, we identify the 
sequence  of the  allopeptide that is presented by a  mutant 
class I molecule, K bin3 to the well-defined T  cell receptor 
present on 2C T  cells  (13,  14).  This is the second MHC/ 
peptide complex that is an alloantigen for 2C T  ceils.  The 
previously defined  alloantigen  is  the  p2Ca  peptide  in  the 
context of the L  d class I molecule. This is the first descrip- 
tion of a pair of distinct MHC/peptide complexes that are 
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the basis for future studies to define the nature of TCR  in- 
teractions with multiple MHC/peptide  complexes. 
Materials and Methods 
Mice and Cell Lines.  Mice used in these studies were C57BL/ 
6Kh-H-2 I'm8 kindly  provided  by  Dr.  P.  J.  Wettstein,  (Mayo 
Clinic, Rochester, MN) and maintained in the Mayo Clinic Ani- 
mal Facility. BW5147  and T2  cells  were  transfected with K  bin8 
and K bin3 respectively using constructs described previously (15, 
16).  T2 and T2K  b"'8 cells were kindly provided by Dr.  L.  Sher- 
man (Scripps Institute, La Jolla, CA). T2L  a cells were kindly pro- 
vided by Dr. P. Cresswell (Yale University, New Haven, CT). 
Peptides Isolation and Synthesis.  Peptide  extracts  were  gener- 
ated by immunoprecipitation of the class I molecule from cell de- 
tergent lysates  or dounce homogenized thymic lobes from K b~8 
expressing cells from mice or BW5147 K bins transfected cells us- 
ing two K b specific antibodies Y-3 and K10.56 (17,  18).  Protein 
A-Sepharose (Sigma Chemical Co.,  St.  Louis, MO)  was used to 
retain antibody-MHC  complexes.  The  beads were  washed  and 
antibodies eluted using 0.2 N  acetic acid. Peptides were eluted in 
10% acetic acid. Eluted peptides were separated by a Centricon 3 
column filtration system (Amicon, Beverly, MA) and lyophilized 
as previously described (19). 
Peptides  were  synthesized using solid phase  chemistry as de- 
scribed previously with N"-9-fluorenylmethoxycarbonyl (Fmoc) 
protected L amino acids (20).  Each synthetic peptide,  excluding 
the two degenerate libraries, was purified to a single homogenous 
peak by reverse-phase HPLC. 
HPLC Fractionation and Peptide Sequence.  K b'n8 class I eluted pep- 
tides  were  fractionated  on  two  sequential  RP-HPLC  systems. 
The  fractionation  was  carried  out  on  an  Applied  Biosystems 
model  130A  instrument,  using an  Aquapore  OD-300  reverse 
phase  column (2. l  ￿  220 mm)  (Brownlee, Applied Biosystems 
Inc.  [ABI],  Foster City,  CA)  as previously described  (19).  The 
initial buffer system consisted of A and B, which were 1% trifluo- 
roacetic  acid  (TFA)/5%  acetonitrile/H20  and  0.1%  TFA/40% 
acetonitrile/H20,  respectively.  A  linear  gradient  from  0-80% 
buffer B  was  used over 80 min. The flow rate was  0.2 ml/min 
and either 0.5 or 1 min fractions were collected. Biological activ- 
ity of HPLC fractions was determined in chromium release assays 
as described below. The second HPLC buffer system was identi- 
cal to the first except hydrochloric acid was used in place of TFA 
and a linear gradient starting at 10 min from 30 to 70% buffer B 
was used over 60 rain. The final HPLC system that was employed 
used the same instrument, column, and flow conditions, but the 
buffers and gradient were as follows: buffer A and B compositions 
were  50  mM acetic acid/5% methanol, titrated to pH  3.9 with 
NH4OH and 50 mM acidic acid/50% methanol, titrated pH 3.9 
with NH4OH,  respectively. A  linear gradient from 5  to  80% B 
was used over 75 rain. Edman degradation was perfomled using an 
ABI Procyse 492 Protein Sequenator (Perkin Elmer, Norwalk, CT). 
Cytotoxicity Assays.  CTLs used in this study were either lines 
established from 2C transgenic mice (21) or the original 2C CTL 
clone (22)  kindly provided by D.  M.  Kranz (University of Illi- 
nois, Urbana, IL).  Briefly, splenocytes from the transgenic mice 
or the 2C clone (DK) were stinmlated weekly with lethally irra- 
diated BALB/c stimulators in the presence of rat concanavalin A 
snpernatant and rlL-2. A standard 5-h SlCr release assay with 3 X 
103 targets/well was employed. When peptide was added, targets 
were incubated with 2-7 I.zl of each HPLC purified peptide frac- 
tion or synthetic peptides for 0.5-1  h  before addition of effector 
cells. Percent specific lysis was calculated as follows: (experinwntal 
lysis -  spontaneous lysis)/(maximum release -  spontaneous lysis) 
x  I00. 
Mouse MLRQ-like Gene Sequena, and Tran~,ction.  Total  RNA 
was isolated from BW5147 and B6 spleen cells using either TRIzol 
reagent,  (GIBCO BRL,  Gaithersburg, MD)  or guanidium-thio- 
cyanate extraction followed by cesium chloride gradient purifica- 
tion (23),  respectively. First strand cDNA was synthesized using 
oligo-dT primers with the cDNA Synthesis System Plus (Amer- 
sham  International,  Amersham,  UK).  cDNA  was  synthesized 
from 20 mg total RNA. The single stranded cDNA was used in a 
PCR reaction. The primers were designed based on the analogous 
sequences  of  human  and  bovine  genes:  5'-CCTTTCCAG- 
TAAGCTTCCTCTGCCGCAAACATGCTCCGCCAGATC- 
ATCGGG-3'  and  5'-ATCGAGCTATGCGGCCGCTGGT- 
TAAGTGGAAAATTGTGCGGAT-3'. The  amplified product 
was cloned into the HindIII and NotI sites of pRc-CMV (Invit- 
rogen,  San Diego,  CA).  Sequence data  was  obtained using the 
fluorescent dideoxynucleotide method and run on an automated 
377 DNA sequencer (ABI). The sequences were confirmed by two 
independent PCR amplifications and cloning of the MLRQ genes 
from both BW5147 cells (AKR) and C57BL/6 spleen cells. 
K bin3 L cell generation was described previously (15).  MLRQ 
cDNA was transfected into the K bin3 L cells, and 1 l  individual cell 
clones  were  picked  after  selection  in  400  ~g/ml  G418.  Cells 
were  then screened for retention of the K bI''3 molecule by flow 
cytometry to detect an engineered epitope using the monoclonal 
antibody, 28-14-8 (24). 
Hybridoma Assay.  The 2C CTL hybridoma was provided by 
P.D.  Gottlieb (University of Texas at Austin, Austin, TX).  This 
hybridoma, which was derived from the 2C T  cell, has the same 
specificity as the 2C  cytotoxic T  cell clone and secretes  IL-2 m 
response to cells bearing the alloantigens L  a and K b'''3. Hybridoma 
and target cells were combined in 96-well microtiter plates at an 
effector to target ratio of 1:2 (1  X  105 effectors and 2  X  10 ~ tar- 
gets).  After incubation for 24 h at 37  ~  cells were pelleted and the 
supernatant removed for quantitation of IL-2 in a standard bioas- 
say (25) using the IL-2-dependent T  cell line, HT-2 (26). Briefly, 
50  bd of the  reaction supernatant was  added to  1 X  104  HT-2 
cells  in  100  bd,  and incubated for  18  to  24  h  at  37  ~  . 2  b~Ci of 
[3H]thymidine  (Amersham,  Arlington Heights,  IL)  was  added. 
HT-2 cells were allowed to incorporate radio label for 6 h before 
harvesting onto filters  and quantitation in a Matrix96 Direct Beta 
Counter  (Packard  Instrument Co.,  Downers  Grove,  IL).  Each 
data point represents the mean of triplicate samples. 
RNA Hybridization Analysis.  RNA from 11 cell lines transfected 
with the MLRQ cDNA was isolated using the TRIzol Reagent. 
Briefly, we loaded 15 ~g of total RNA from each cell line onto a 
fomaaldehyde gel (1.5 % agarose,  1.1 I% Fomaaldehyde, 1 ￿  MOPS 
buffer,  pH  7.0;  10￿  MOPS  is  0.2  M  (3-(N-morpholino)-pro- 
panesulfonic acid),  0.05  M  sodium acetate,  0.01  M  EI)TA).  The 
size separated total RNA was transferred onto a GeneScreen Plus 
(NEN  Research  Products,  Boston,  MA)  nylon filter,  baked  at 
80~  for 2 h, and prehybridized in a water based solution (1.0% 
SDS,  1.0 M  sodium chloride,  10%  dextran sulfate)  at  60~  for 
"~18  h.  A  32p-oc-dCTP  labeled probe  was  prepared  using the 
Random  Primers  DNA  Labeling System  (G1BCO  BILL).  The 
template that we used to label the probe was a 262-bp Sphl frag- 
ment isolated from the pRc/CMV vector. This fragment was lo- 
cated downstream of the MLRQ cloning site and included 95% 
of the polyadenylation signal. The labeled probe was specific fbr 
the 3' untranslated portion of the transfected MLP, Q  transcripts 
1018  Degenerate Allorecognition by the 2C TCK 70% 
g 
rr 50~- 
E 
~  40%- 
o 
fro 30%- 
o 
ID 
~-) 10%- 
0% 
60% 
g 
_~  50%- 
r  40%- 
~o~- 
cz 
co  o%- 
-1o%  1 
i  i  i  i  i  i  t  i  i  r  i  '  i  t  i  t  i  I  i  i  i  i  i  i  i  }'- 
7  lO  13  16  19  22  25  2S  31  34  37  40  43  46  49  52  55  58  61  64  6"7  70  73  76  "/9 
Fraction Number (minutes) 
B 
'  9  '  '  '  '  '  '  23  ....  33  35  '  '  '  13  45  7  11  13  15  17  19  21  25  27  29  31  37  39  41  7 
Fraction Number (minutes) 
Figure  1.  Preparative scale kP-HPLC  fraction- 
ation and cytotoxicity assay of peptides  eluted from 
K bn's molecules reveals  one  2C-K  t'm3 active peak. 
(A) Peptides were eluted from 1 ￿  10  TM K  bmu trans- 
fected BW5147 cells and subsequently HPLC frac- 
tionated using the  acetonitrile/TFA buffer system 
as described  in the materials  and methods. 5 I-~l of 
each fraction was then tested in a cytotoxicity assay 
with 2C  T  cells from transgenic  mice as effectors 
and T2K  bin3 cells as targets. E:T was 6:1. The peak 
at 3.5 rain is TFA and causes lysis of targets without 
addition of effector  cells. (B) The active fractions 
from  three  independent TFA/acetonitrile separa- 
tions of K  b''u eluted peptides were  combined and 
fractionated using the HCl/acetonitrile buffer sys- 
tem described  in Materials and Methods. A total of 
2.2 ￿  10  TM  K  b'ls cells and thymic extracts from 48 
K  b'''s mice were used in the peptide elution. Seven 
~1 of each fraction was then tested in a cytotoxicity 
assay as above. 
and did not hybridize to the endogenous MLR.Q  transcript. We 
added the probe to the prehybridizing filters, and hybridized for 
20 h,  at 60~  To wash the filters, we  used two  changes of 2X 
SSC  (20X  SSC is 3.0 M  sodium chloride, 0.3 M  sodium citrate) 
as  an initial wash  at  26~  for  5  min  each,  then washed in 2X 
SSC,  1%  SDS  under stringent conditions at  60~  for  30  rain. 
The stringent washing was repeated until the level of background 
radioactivity was minimal. As a  P,  NA hybridization control, we 
probed parallel blots with a random primer labeled probe specific 
for the ubiquitously expressed gene, GADPH. 
Results 
Isolation and Characterization of 2C-I~  "'s Allopeptide.  Previ- 
ously, we have shown that K b, K bin3 and K b','8 class I mole- 
cules  all  contain  a  single  R.P-HPLC  fractionated  peptide 
peak that sensitizes T2K 6m3 cells to lysis by 2C  T  cells. We 
define this as the 2C-K bin3 allopeptide fraction,  To  identify 
and sequence the 2C-K bin3 allopeptide, a T  cell cytotoxicity 
assay (chromium  release) was used.  As described previously 
(19),  peptide  eluates  were  added  exogenously  to  TAP 
Table  1.  Edman Sequence Analysis 
Peptide name  P1  P2  P3  P4  P5  P6  P7  P8 
Endogenous peptide 
sequence analysis 
Synthetic L library 
Synthetic V  library 
Synthetic peptide 
sequence analysis 
A, E, G,  Q  Y  E,K  F  Y  Q,S  L,V 
Q,S 
ND  0.5  0.4  0.2, 0.2  0.3  0.3  <0.3  <0.3 
X  O  Y  E,K  F  Y  Q,S  L 
X  Q  Y  E,K  F  Y  Q,S  V 
A, D, E,  Q  Y  K  F  Y  S  t 
S,T 
ND  10  10  7  6  4  0.6  0.1 
Numbers after the single letter amino acid designation represent the yield (pmol) of each amino acid present in the sequence analysis. No concentra- 
tion is shown for P1 due to the presence of background peaks commonly observed; A, S, and D. X indicates all 2(3 amino acids were represented in 
Pl of the peptide libraries. 
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Figure  2.  The leucine  and  valine  degenerate  libraries work  equiva- 
lently  in  sensitizing T2K  b'''3 and  T2K  l~'''1~ cells to lysis by 2C  effectors. 
Targets were T2K  b'"-~ (/eft) and T2K  b"l' (righO cells, and effectors were 2C 
T cells from transgenic mice. The E:T was 6:1. Peptides were incubated 
with targets one h before addition  of effector cells. A standard 5-h chro- 
mium release assay was used. V indicates valine library, and  L indicates 
leucine library. See Table l for complete sequence information. 
transporter-deficient  target  cells  (T2)  expressing  the  rele- 
vant  MHC  class  I  molecule  and  mixed  with  2C  effector 
cells. The ability of the peptides to sensitize the target cells 
to  lysis was  then  determined.  Only  when  the  biologically 
active  peptide  was  present  did  2C  T  cells  lyse  the  target 
cells.  In repeated  runs,  we noted  that  K bm~ peptide  eluates 
consistently  yielded more  2C-K bin3 allopeptide  than  either 
K b or K b"3 eluates; the number of cells required to generate 
detectable  peptide  was  an  order  of magnitude  lower  than 
for K b or K bin3. Because  of this observation,  we chose  cells 
bearing  the  K bins  molecule  as  the  source  for  preparative 
scale  isolation  of peptides.  Peptides  from  the  thymuses  of 
48 K bn,s mice and 2  ￿  10 "~ Kb"~S-bearing cells were eluted, 
subjected to HPLC  separation  (acetonitrile/TFA), and sub- 
sequently  the  sensitization  assay  with  T2K  ~''''3 cells  as  tar- 
gets.  Fig.  1 A  is an  example of one run  of the sensitization 
analysis.  The  active  fractions  from  each  HPLC  run  were 
combined  and  fractionated  on  a  second  HPLC  buffer  sys- 
tem  (acetonitrile/HC1).  The  sensitization  assay  was  again 
used to identify the biologically active peptide fraction (Fig. 
1  /3).  In  both  HPLC  runs,  only  one  active  fraction  was 
present,  indicating  that  there  was  a  single,  dominant  pep- 
tide. 
Peptide Sequendng.  The  active  HPLC  fraction  at  36.5 
min was lyophilized and  sequenced  using Edman  degrada- 
tion.  The results are represented  in Table  1.  Previous stud- 
ies  have  indicated  that  fractions  enriched  by  these  proce- 
dures  typically contain  many peptides  and  often  dominant 
peptides  can be visualized by sequence  analysis  of enriched 
pools (27).  The 2C-K b''3 allopeptide  fraction had a  distinct 
amino acid composition,  and the amino acid assignments  at 
P2,  P3,  P5,  and  P6  were  unambiguously  determined.  At 
P4, P7,  and P8, two amino acids were present in equimolar 
concentrations  and  definite  residue  assignments  for  those 
amino acid positions  could not be determined.  The amino 
acid present at P1  of the peptide was also unclear due to the 
common  background  peaks  present  in  the  first  round  of 
cleavage,  To  determine  if  the  2C-K  bin3  allopeptide  was 
among these peptide possibilities, we made two degenerate 
synthetic  peptide  libraries.  Table  I  indicates  the  composi- 
tion  of the  peptide  libraries.  We  tested  both  libraries  in  a 
chromium release assay, and they sensitized T2K b''3 cells to 
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Figure  3.  One  major  active  peak  is 
present in the degenerate synthetic pep- 
tide leucine gemisch after two rounds of 
sequential  HPLC  fractionation.  (/t)  20 
b~g  of  the  degenerate  peptide  library 
(leucine  at  178)was  fractionated  using 
the TFA/acetonitrile buffer system, and 
7 b~l of each  HPLC fraction were then 
tested in a chromium release assay as de- 
scribed m  Fig.  1 A.  (B)The  two major 
active  HPLC  fractions  at  38.5  and  39 
ulin were then run on tile second acetoni- 
trile/HCl HPLC buffer system and 7 ~1 of 
each fraction tested in the chromium re- 
lease assay. The traction  from 39 mm is 
represented  in  the  figure.  Identical  re- 
suits were  obtained  for  the  fraction  at 
38.5 rain.  The continuous  line indicates 
the absorbance at 214 nm, and the solid 
black line with discrete data points indi- 
cates the specific chromium release. 
1020  Degenerate Allorecognition by the 2C TCP,, Figure 4.  Acidic  amino acid residues at P1 are to be more efficient  at 
inducing lysis when presented in the K  broIl molecule. Synthetic peptides 
containing the sequence QYKFYSL for amino acids at P2-P8, but vary- 
ing at P1 were titrated in a chromium release assay with either T2K  b'"3 or 
T2K  b'''H cells as targets. E:T was 6:1. Peptides were incubated one h with 
targets before addition of 2C effector cells from transgenic mice. Using 
the single letter amino acid code, the peptide is indicated by the residue 
present at P1. 
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Figure 5.  The biologically  derived K b'n3 allopeptide elutes in the same 
fraction as  the  synthetic EV peptide. The  third HPLC buffer system 
(methanol) with high resolving  capacity was used to compare the elution 
of the biologically  derived 2C-K  b':~3 allopeptide to three synthetic pep- 
tides-EV, EQYKFYSV; EL, EQYKFYSL, and DV, DQYKFYSV. K  bin3 
peptides from 1.3 X 10  '~ K  bin3 Con A blast cells were eluted and subjected 
to the third HPLC system. Then, each fraction  was tested on T2K  b'"3 cells 
in the standard chromium release assay (10 p,1). 2C T cells from transgenic 
nfice were used at an E:T ratio of 3:1. Solid line indicates  the absorbance 
at 214 nm of the three synthetic peptides. Peptides were run indepen- 
dently and in pairs to identify  their elution order before this separation. 
lysis by 2C  T  cells efficiently and equivalently, indicating 
that the peptide of interest was a dominant peptide in the 
sequenced fraction.  However,  we  could not discriminate 
between the two peptide libraries using 2C T  cell recogni- 
tion of T2K  bin3 target cells (Fig. 2 A). 
Previously,  others  have  shown  that  the  mutant class  I 
molecule, K broil, is also a ligand for the 2C T  cell receptor 
(21, 28). In these studies, 2C effectors were shown to have 
lower affinity for the K bm~l molecule. The K bin3 and K bin11 
molecules differ  by two  amino acids.  While they have  a 
common mutation at  position 77,  K b"3  has  an additional 
mutation at  amino acid  89,  and K bm~  has  a  mutation at 
amino acid  80.  It  is  this  difference at  position 80  which 
likely results in the difference of affinity in binding the 2C 
TCR. Assuming that K bm~ presents the same allopeptide as 
K bin3, we  chose  to  test  T2K  bm~  as  targets  in the  peptide 
sensitization assay  because  we  anticipated that  2C  TCR 
recognition of K broil would be more discriminatory at the 
peptide level. Fig. 2  B illustrates that even on T2K  bml~ tar- 
gets,  the two peptide libraries were equally efficient at in- 
ducing lysis. 
We chose  the leucine library to  elucidate the definitive 
2c-m  bin3 allopeptide sequence by biochemical means, be- 
cause leucine is a more common amino acid residue at po- 
sition 8 in the K b binding motif (29). We ran the library of 
80  degenerate peptides  on  the  initial HPLC  acetonitrile/ 
TFA system (Fig. 3 A). One major active peak at 38.5-39.0 
min was capable of sensitizing T2K  bin3 to lysis by 2C effec- 
tors. This elution time was also commonly observed in the 
endogenously isolated allopeptide on the TFA/acetonitrile 
buffer system. We independently subjected the fractions at 
38.5  and 39  rain to  a  second round of HPLC  separation 
(acetonitrile/HC1) and again tested the fractions in a chro- 
mium release  assay  (Fig.  3  B).  Similar elution patterns in 
both absorbance and activity in the chromium release assay 
were  observed for the  38.5  and 39  minute fractions.  Be- 
cause these two fractions were indistinguishable, we chose 
to  sequence the  active peptide(s)  from the  fraction at  39 
min by Edman degradation. The sequence analysis of the 
fraction is represented in Table 1.  Mass spectrometry data 
and  capillary  electrophoresis  independently revealed  that 
there were between 1-4 peptides present in the sequenced 
HPLC  fraction  (data  not  shown).  As  before,  the  back- 
ground in cycle one of the  analysis prevented a  definitive 
call for  position one  of the  peptide.  It  should be  noted, 
though,  that the  only amino acid residue present in both 
sequences at position one that was not a background peak 
was glutamic acid. In addition, the positions 4 and 6 were 
definitively lysine and serine, respectively. Only two posi- 
tions remained to be identified, Pl and P8. 
Determination of Amino Acid Position 1.  Common back- 
ground peaks present during the Edman sequencing process 
made  the  determination of the  residue at  amino acid  P1 
difficult.  In  an  attempt  to  find  the  biologically relevant 
peptide, we synthesized all five possibilities that arose in the 
second sequence determination from the synthetic leucine 
library. These peptides were defined as AL, DL, EL, SL and 
TL. We tested the biological activity of all five peptides in 
our sensitization assay  on T2K  bin3. Fig. 4  illustrates that all 
five peptides were effective in sensitizing T2K  bin3 to lysis by 
2C T  cells, while the same peptides had no effect on T2L  a 
or T2K  bin8 sensitization (data not shown). Fig. 4 also shows 
that unlike the T2K  bin3 targets, T2K  bran presented the five 
peptides  to  2C  T  cells to varying degrees.  The two  most 
effective peptides were EL and DL, and the TL peptide also 
sensitized T2K  bm~7 to lysis but to a lesser extent. 
Comparison  of the  Biologically Derived  Peptide to  Synthetic 
Peptide.  To  further  define  the  2C-K  bin3 allopeptide,  we 
compared the candidate synthetic peptides to  the biologi- 
cally derived peptide. Because we had not conclusively de- 
termined the  amino acids at  position one or eight of the 
peptide, we  ran peptides eluted from K b'"3 and K b's on a 
1021  Tallquist et al. Table 2.  Database Search Results 
Peptide name  Pl  P2 P3 P4 P5 P6 P7  P8 
Synthetic peptide 
sequence analysis  A,D,E,  Q  Y  K  F  Y  S  V,L 
S,T 
Rabbit lipopolysaccharide 
binding protein  A  Q  Y  K  F  Y  S  L 
Murine lipopolysaccharide 
binding protein  G  Q  Y  E  F  H  S  L 
BovineMLRQ  D  Q  Y  K  F  Y  S  V 
MurineML1KQ  E  Q  Y  K  F  Y  S  V 
Sequence data for rabbit lbp and bovine mlrq were obtained from Gen- 
Bank. The accession numbers are M35534  and X64897,  respectively. 
Murine  lbp sequence was kindly provided by P. Tobias, Scripps Insti- 
tute,  La Jolla,  CA.  The  murine  nrlrq  sequence  was  obtained  from 
cDNA generated in our lab from C57BL/6  spleen cells. 
HPLC  instrument  using methanol  gradient solvent system 
and compared the  elution time to that of several synthetic 
peptides. The methanol system was chosen because it pro- 
vided sufficient resolution of three  likely synthetic  candi- 
dates; EL,  DV,  and EV.  We  then  compared the retention 
time of the biologically derived, active peptide to  the syn- 
thetic retention times. Fig. 5 illustrates that the biologically 
derived  peptide  from  K bin3 eluted  at  the  same  retention 
time as the EV peptide with similar results for peptides de- 
rived from K bins and K b (data not shown). 
Data  Base Homologies.  We  next  searched  databases  for 
possible protein sources  of the  2C-K  b'~3 allopeptide. Two 
homologous  peptides  were  identified.  One  peptide  was 
from bovine ML1KQ. This protein contained a peptide that 
matched the 2C-K  bin3 allopeptide sequence at six out of the 
eight  definitive  amino  acids  and  corresponded  with  the 
possibilities at  Pl  and  P8  (Table  2).  ML1KQ,  is a  nuclear 
encoded mitochondrial protein that is part of complex I of 
the  NADH  ubiquinone  complex.  Little  is  known  about 
this protein's function  or trafficking (30).  The  mouse  ho- 
mologue  had not been characterized; we  therefore cloned 
and  sequenced  the  cDNA.  Fig.  6  reveals a  sequence  from 
the  mouse  that  is  highly  homologous  to  the  bovine  se- 
quence  and  sequences  that have  been  cloned as  expressed 
sequence tags from human cDNA. The murine sequence is 
sinfilar to both the human  and bovine reported sequences, 
contains a peptide that is consistent with the partial amino 
acid sequence  defined in  our peptide  eluates,  and  has  the 
identical  sequence  as  the  synthetic  peptide  that  migrates 
with  the  biologically active  eluted  peptides.  The  second 
peptide  sequence  match  was  from  the  rabbit lipopolysac- 
charide binding protein (LBP) 1 (Table 2). We obtained the 
sequence of the murine homologue of LBP, and unlike the 
rabbit  peptide,  it  differed  from  our  allopeptide  sequence 
I  Abbreviation  used in this paper: LBP, lipopolysaccharide  binding protein. 
Figure  6.  Partial  sequence obtained  for the  mML1KQ protein  with 
comparison to bovine and human homotogues. The cI)NA sequence of 
lnouse is shown in the top line, flanked by the 5' and 3' primers from the 
bovine and human cDNA sequence (clear boxed region). The predicted 
alnino  acid  sequence  of mouse  MLRQ  is  compared  to  the  corre- 
sponding amino acid sequences from human and bovine. Dashes indicate 
the same amino acid is present as in the mouse. Gray shaded box region is 
the sequence that agrees with the 2C-K  b'~'-s  allopeptide sequence. * t~,ep- 
resents a stop codon. ￿9  Indicates lack  of corresponding amino acid. First 
seven amino acids were not determined for the mouse. These sequence 
data for human, bovine, and murine are available from GenBank under 
accession numbers z36856, x64897, and u59509, respectively. 
data at three positions (Table 2)  (P.  Tobias, personal com- 
munication).  To  verify that  this peptide was  not  a  candi- 
date, we synthesized it and tested its biological activity on 
T2K  u'13 using 2C  effectors (data not shown).  Even at con- 
centrations of 0.5 mg/ml the mLBP peptide, GQYEFHSL, 
did not sensitize T2K  6m3 cells to lysis by 2C T  cells. 
Identifying the  ML1KQ  protein as a  potential precursor 
of the 2C-K  bin3 allopeptide could not be taken as evidence 
that  the  biologically active  peptide  is  processed from  the 
protein. Previously, we had shown that the 2C T  cell's rec- 
ognition  of K 6m3  transfected  L  cells  is  often  sub-optimal, 
therefore we predicted that by increasing the levels of the 
allopeptide we  may be able to  upregulate  the  recognition 
of K b''3 L  cells as targets.  To  test this possibility we  trans- 
fected K bn~3 L  cells with murine MLRQ  cDNA under the 
control of the CMV promoter.  We identified eleven indi- 
vidual clones that had  levels of K bin3 expression that  were 
comparable to the levels of expression on the parent K b'''3 L 
cell  (data  not  shown).  We  then  tested  the  clones  for  en- 
hanced recognition by 2C hybridomas and CTLs (Fig. 7, A 
and B, respectively). Clones 1, 2, 3, 4, and 8 had the ability 
to  cause  increased  levels  of cytokine  production  by  the 
3D9  hybridoma and were lysed more efficiently by the 2C 
CTL when compared to the parental L cell clone. We then 
isolated mtKNA  from  the  eleven  MLRQ  cell  clones  and 
the parental K bin3 L  cell and determined the levels of trans- 
fected ML1KQ mRNAs by Northern blot analysis (data not 
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expressed  MLRQ  are  better  targets  than 
wild-type  K  b'~3  L  cells. Kbm3-expressing L 
cells transfected  with MLRQ  cDNA were 
used as targets  in a hybridoma assay (/t) and 
a chromium release assay (B) as described  in 
Materials  and  Methods.  Effector  to  target 
ratios were 2:1  for the 3D9 hybridoma assay 
and effector  cells for chromium release assay 
were the original  DK 2C clone. 
shown).  We  found  a  complete  correlation  between  the 
cells  that  had  enhanced  recognition  as  mentioned  above 
and those that had detectable levels of pRc-CMV/MLRQ 
mRNA.  These  data indicate  that not only does mMLRQ 
contain  a  peptide  with  identical  sequence  to the  2C-K  bin3 
allopeptide,  but  that  this  peptide  can  be  processed  from 
MLRQ  and presented by the K bin3 class I molecule to 2C T 
cells.  The sum of these  results supports the hypothesis that 
the  peptide,  EQYKFYSV,  is  the  2C-K  bin3  allopeptide, 
henceforth known as dEV-8. 
Discussion 
In recent years,  the  techniques  of peptide  isolation  and 
the understanding of T  cell recognition have allowed a de- 
tailed  view  of  allorecognition  at  the  molecular  level. 
Clearly,  there  are  a  variety  of possible  TCR  and  MHC/ 
peptide complex interactions in allorecognition. This study 
describes  an additional  aspect;  the  ability  of a  single  TCR 
to  recognize  two  very  different  MHC/peptide  structures 
with high specificity. The 2C T  cell is a highly studied cy- 
totoxic  T  cell,  whose  allopeptide  in  the  L  a molecule  was 
identified  previously  (31).  We  have  determined  a  second 
aUopeptide, designated dEV-8, for the 2C TCR  that is pre- 
sented  in  the  K bin3 molecule.  The  dEV-8  sequence  is  dis- 
tinct from P2Ca, and the recognition of dEV-8 by the 2C 
TCR  is specific to the K bin3 molecule.  How a single TCR 
can interact effectively with two very different MHC/pep- 
tide complexes is an interesting question.  One possible ex- 
planation for this cross recognition is that there is a one to 
one  correspondence  between  conserved  residues  of K bin3 
and L d, and these amino acid residues are contact points for 
the 2C T  cell receptor.  However, another possibility is that 
the  2C  TCR  contacts  different  residues  on  K bin3 and  L a, 
and cross recognition is simply a result of the T  cell receptor's 
inherent ability to associate with an MHC molecule (32). T 
cells  are  presumably  selected  to  have  moderate  affinity/ 
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avidity  for  the  MHC  molecule  structure  (33,  34),  and 
therefore it may not be surprising that more than one pep- 
tide may provide the added contacts to increase the affinity 
of the TCR  for any given MHC  molecule to the point of 
antigenic recognition. Infomlation about the orientation of 
the TCR  on these class  I molecules will come from struc- 
tural studies using site directed mutagenesis and x-ray crys- 
tallography. No matter which of these scenarios causes the 
cross recognition, understanding this phenomenon may ex- 
plain the high frequency of alloreactive T  cells. 
Even though 2C TCR  recognition is degenerate regard- 
ing its two alloantigens, it appears to be very specific for the 
peptides  within  a  given  MHC  molecule.  Only  a  single 
HPLC peptide fraction from K bin3 or K bin8 class I molecules 
was  observed  in  the  highly  sensitive  cytotoxicity  assay, 
even when peptides  from 1  X  101{} cells  were  analyzed. A 
similar circumstance was seen for the L d allopeptide, where 
only three active HPLC fractions were present,  and one of 
the peaks was simply a longer precursor of P2Ca (35).  The 
identity  of the  third  peak  is  unknown.  In both  systems,  a 
discrete  number  of peptides  from the  entire  repertoire  of 
isolated peptides were identified for activity in their respec- 
tive class I molecules. Further support for the 2C TCR's fi- 
delity was observed when an analogue  of P2Ca known as 
P2Ca-Y4 was identified.  P2Ca-Y4 differs from P2Ca at P4, 
where  a  tyrosine replaces  a phenylalanine,  and yet the  2C 
TCR  can distinguish between these two similar peptides in 
the  context  of K b (36).  Similarly,  the  mLBP  peptide  with 
homology to  dEV-8  was  an  ineffective  allopeptide  when 
bound to K bin3, providing more evidence that although 2C 
TCR  has degenerate  recognition of two class  I  molecules, 
the peptide recognition is extremely specific. 
We are confident that dEV-8 is at least one 2C-K  bin3 al- 
lopeptide  for  several  reasons.  The  sequence  of  dEV-8 
agrees with the predicted K b motifs; Y  or F at P5, Y  at P3 
and a hydrophobic residue  at P8. Even though we derived 
the sequence from the K bn'8 bound peptides,  we have pre- viously shown that a single HPLC fraction from K b, K bin3 
and  K u'''a eluates  contained  the  2C-K  bin3 allopeptide  (19) 
demonstrating  that the  same peptide  species  can be found 
in K urn3. This peak eluted in identical positions on two very 
different  HPLC  systems,  and  the  peptide  we  have  identi- 
fied  co-migrates with  the  biologically isolated  species.  Fi- 
nally,  identifying  a  potential  protein  precursor,  MLRQ, 
which when expressed in cells bearing the K bin3 class I mol- 
ecule  can  up-regulate  recognition  by  2C  cells  also  adds 
support  that  this  sequence  is  the  endogenous  peptide. 
While all this data favors the hypothesis that MLRQ  is the 
dEV-8 peptide source, it is still possible that more than one 
protein contains the same peptide or a similar peptide capa- 
ble of stimulating 2C T  cells.  This possibility is accentuated 
by the fact that MLRQ  is a member ofa multi-gene family 
in the mouse (data not shown). 
It is interesting  that  P2Ca  and  dEV-8  are derived from 
mitochondrial proteins. While this may be a coincidence, it 
may  be  significant  that  a  third  allopeptide,  ND-1,  for  a 
non-classical  class  I  molecule  is  also  mitochondrially  de- 
rived (37). Because three of the identified allopeptides have 
a mitochondrial origin,  there is a possibility that organelles 
such as mitochondria play a predominant role in providing 
polymorphic peptides  to the  class  I  presentation  pathway, 
though this is not evident from peptide elution studies (38, 
39).  Another  possibility  is  that  these  peptides  have  been 
identified  because  they  are  abundant,  ubiquitous,  and/or 
have  high  turnover  rates.  Only  further  investigation  will 
determine  if there  is  a  unique  aspect  to mitochondrial  al- 
lopeptides. 
The finding that a selfpeptide  that is present in the thy- 
nms is also an allopeptide when presented in a mutant mol- 
ecule  suggests  that  there  may  be  a  relationship  between 
mutant recognition and thymic selection. K bin3 and K b dif- 
fer by only two amino acid positions, 77 and 89. According 
to crystal structure data and mutational analysis, amino acid 
position 89 plays no role in peptide binding or T  cell rec- 
ognition  (15,  21,  40).  If dEV-8  is bound  to both  K b and 
K bin3 and seen by the 2C TCR,  the amino acid at position 
77 is the residue  responsible  for the difference in recogni- 
tion.  Assuming that K b and K b'1'3 bind dEV-8 with  similar 
affinities  and  that  the  affinity/avidity model  of thymic se- 
lection pertains  to 2C thymocytes, one would predict that 
the 2C TCR would have a higher affinity for K bin3 than K b 
when dEV-8 is bound. Thymocytes of 2C transgenic mice 
are  negatively selected  in  the  presence  of K bin3, but  posi- 
tively selected  in the presence  of K b.  If the  affinity of the 
thymocytes for K b is increased by addition of a CD8 trans- 
gene, then 2C thymocytes become negatively selected  (41, 
42).  This data suggests that K b may bind  the same peptide 
as K bin3 but that the affinity of the  2C TCR  for K u under 
normal conditions only elicits positive selection. Currently, 
2C  TCR  affinity intbrmation  is available for P2Ca bound 
in  both  L a and  K b (43,  44),  but  there  is  no  data  for 2C 
TCR affinity for K u with dEV-8 bound. This affinity infor- 
mation,  in  addition  to  thymic  organ  culture  studies,  may 
reveal  if dEV-8  plays  a  role  in  selecting  2C  thymocytes 
when bound to K b and if it is solely responsible for the se- 
lection of2C thymocytes. While only one allopeptide peak 
was present in the HPLC separation of the eluted peptides, 
selection of2C thymocytes may rely on a group ofpeptides 
being presented for positive selection. A sum of low at}inky 
interactions  totaling a  moderate  avidity would also  fit the 
current models of positive selection. Therefore, dEV-8 may 
be one of many peptides  bound in K b capable of selecting 
2C  thynmcytes.  This  possibility  can  only be  addressed  by 
creating a mouse deficient in MLRQ. 
We  have  illustrated  a  unique  system where  one  T  cell 
receptor sees two distinct MHC/peptide complexes as anti- 
gens.  This  system  demonstrates  the  versatility  of a  single 
TCR  to  recognize  two  different  MHC  molecules,  but 
maintain its peptide specificity. If it can be assumed that all 
TCRs possess  a sinfilar ability to cross react with  nmltiple 
MHC/peptide  complexes, this may be one explanation for 
the high frequency of alloreactive T  cells.  In addition,  be- 
cause  the  allopeptide  is  also a  ubiquitous  self peptide,  this 
system may prove  to be a  useful  tool to address  questions 
regarding positive selection, tolerance, and autoimmunity. 
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